FDA 483 OBSERVATION · #90 OF 1,945 MOST-CITED

Environmental Monitoring System

FDA cited this observation 314 times across 267 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs314
BY FISCAL YEAR
FY202620
FY202525
FY202434
FY202327
FY202226
FY202118
FY202010
FY201938
FY201824
FY201733
FY201659

What this observation means, and how to comply

SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.

21 CFR 211.42/113 · EU GMP Annex 1

The environmental monitoring system for a sterile or low-bioburden operation was inadequate — monitoring of the microbial and particulate state of the controlled environment did not adequately verify that contamination controls were working.

Why FDA writes it — Environmental monitoring is how a firm knows its aseptic or clean environment is actually under control. An inadequate EM system means excursions and adverse trends go undetected, so contamination can reach product without warning — a serious sterility-assurance gap.

HOW TO COMPLY
  • Establish an EM program with risk-based sample locations, viable and non-viable monitoring, and defined alert/action levels tied to responses.
  • Monitor at a frequency appropriate to the grade and risk (continuous non-viable in critical zones during operations).
  • Trend results to detect drift, and investigate action-level excursions including organism identification where warranted.
  • Feed EM outcomes into the contamination-control strategy and corrective action.
WHY FIRMS GET CITED
  • Sample locations and frequency not based on risk, so monitoring misses where contamination would occur.
  • Data collected but not trended, so drift within limits goes unseen.
PROFESSIONAL · REMEDIATION PLAYBOOK · SPEQ SYNTHESIS

How to close this finding — and stop it recurring

CHECKING ACCESS

Checking your access…

What this observation is associated with

Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 6.6× the rate of the average FDA-cited firm (51.3% vs 7.8%), across 267 FEI-matched firms.

This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.

CHECKING ACCESS

Checking your access…

How FDA worded it — real examples

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Steril-Gene Life Sciences Private Ltd · Puducherry · Drugs · 2026-08-12

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Alcami Carolinas Corporation · Morrisville, North Carolina · Drugs · 2026-08-11

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Samchundang Pharm Co., Ltd. · Hwaseong · Drugs · 2026-05-19

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Element Materials Technology Boston - Acton Inc. · Acton, Massachusetts · Drugs · 2026-05-04

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

GVS TM, Inc · Covina, California · Drugs · 2026-05-01

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Samson Pharmaceuticals, Inc · Commerce, California · Drugs · 2026-04-29

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Contamination control →Pharma industry →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →